Selecta Biosciences Initiates Phase 2 Clinical Trial of SEL-212, First Non-Immunogenic Biologic in Development for Treatment of Gout

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing a novel class of targeted antigen-specific immune therapies, today announced that it has dosed the first patient in its Phase 2 clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product Read More…

Emulate Announces Strategic Collaboration with Covance to Integrate Organs-on-Chips Technology in Drug Evaluation

posted in: News | 0

Emulate, Inc. announced today a strategic collaboration with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) that seeks to integrate Emulate’s Organs-on-Chips technology into preclinical drug evaluation and testing services. Emulate’s proprietary technology attempts to recreate the natural physiology of Read More…

Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

posted in: News | 0

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) and Tarveda Therapeutics, Inc. today announced an exclusive worldwide license agreement providing for the discovery, development and commercialization by Tarveda of products based on Madrigal’s HSP90 Drug Conjugate program, including the lead clinical candidate, PEN-866. Read More…

ARMO BioSciences Announces Publication of AM0010 Clinical Data in Advanced Solid Tumor Patients in Journal of Clinical Oncology (JCO)

posted in: News | 0

ARMO BioSciences, Inc., a clinical-stage biotechnology company, announced that the Journal of Clinical Oncology (JCO) has published clinical safety and efficacy data on the Company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) in patients with advanced solid tumors. The peer-review Read More…

Selecta Biosciences Announces Publication in Nature Nanotechnology Describing Novel Approach for Improving the Efficacy and Safety Profile of Biologic Drugs

posted in: News | 0

Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, announced today that Nature Nanotechnology has published an article that presents preclinical results from Selecta’s research which demonstrate the broad potential applicability Read More…

Seres Therapeutics and Emulate Announce Collaboration to Support the Development of Novel Microbiome Therapeutics for Inflammatory Bowel Disease and other Serious Conditions

posted in: News | 0

Seres Therapeutics, Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, and Emulate, Inc., a private company commercializing the Organs-on-Chips technology, today announced a new collaboration. Under the terms of the agreement, Seres and Emulate will work to further advance Emulate’s Read More…

1 2 3 4 5 6 8